

10. Pipeline (as of August 3, 2026)

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
Infectious disease	Cefiderocol Tosilate Sulfate Hydrate [US, Japan: Fetroja®] [EU:Fetroja®]	Cell-wall synthesis inhibition (injection)	Gram-negative infection (pediatric)	NDA submission: US (Apr. 2026) EU (May. 2026)	In-house	In-house
			Gram-negative infection	MAA submission: Australia (Dec. 2024)	In-house	In-house
	S-268019 [Japan:Covgoze®]	Vaccine (muscular injection)	Prevention of COVID-19 (Adolescent)	Phase II/III	In-house	In-house
			Prevention of COVID-19 (Children)	Phase I/II/III	In-house	In-house
	S-268024	Vaccine (muscular injection)	Prevention of COVID-19	NDA submission: Japan (Nov. 2025)	In-house	In-house
	S-567123	Vaccine (muscular injection)	Prevention of COVID-19	Phase I	In-house	In-house
	Ensitrelvir Fumaric Acid [Japan:Xocova®]	3CL protease inhibitor (oral)	Treatment of COVID-19 (12 years old and older)	NDA submission: EU (Jun. 2025)	In-house	Japan, global, Taiwan: In-house South Korea: In-house /Ildong Singapore: In-house /Juniper
			Treatment of COVID-19 (Children, 6 to 11 years)	Approval: Japan (Jun.2026)	In-house	In-house
			Post exposure prophylaxis of COVID-19	NDA submission: EU (Jun. 2025) Taiwan(oct. 2025) Approval: Japan(Mar.2026) US(Jun.2026)	In-house	In-house
			Treatment of COVID-19 (Pediatric, 0 to 5 years)	Phase III	In-house	In-house
	Olorofim	Dihydroorotate dehydrogenase (DHODH) inhibition (oral)	Invasive aspergillosis	Phase III	F2G (UK)	In-house/ F2G
	Secutrelvir	3CL protease inhibitor (oral)	Treatment of COVID-19	Phase III	In-house	In-house
		3CL protease inhibitor (long-acting injection)	Pre exposure prophylaxis of COVID-19	Phase I	In-house	In-house
	S-337395	RNA dependent RNA polymerase inhibitor (oral)	Treatment of RSV infection	Phase II	In-house/ UBE	In-house/ UBE
	S-649228	Cell-wall synthesis inhibition (injection)	Gram-negative infection	Phase I	In-house/ Qpex	In-house
QOL Diseases	Naldemedine tosilate [Japan:Symproic®] [EU:Rizmoic®]	Peripheral opioid receptor antagonist (oral, powder)	Opioid-induced constipation (pediatric)	Phase I/II	In-house	In-house
		Peripheral opioid receptor antagonist (oral)	Opioid-induced constipation	Approval: Mainland China (NMPA) (May. 2026)	In-house	In-house
		Peripheral opioid receptor antagonist (oral)	Parkinson's disease with constipation	Phase II	In-house	In-house
	Zatolmilast	PDE4D negative allosteric modulator (oral)	Fragile X syndrome	Phase II/III	Tetra (USA)	In-house
			Jordan syndrome	Phase II	Tetra (USA)	In-house
			Alzheimer's disease	Phase II	Tetra (USA)	In-house
	S-588410	Cancer peptide vaccine (injection)	Esophageal cancer	Phase III	OncoTherapy Science, Inc. (Japan)	In-house
			Bladder cancer	Phase II	OncoTherapy Science, Inc. (Japan)	In-house
	S-488210	Cancer peptide vaccine (injection)	Head and neck squamous cell carcinoma	Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
QOL Diseases	S-588210	Cancer peptide vaccine (injection)	Solid tumor	Phase I	OncoTherapy Science, Inc. (Japan)	In-house
	SR-0379	Promote granulation formation (topical)	Cutaneous ulcer (Pressure ulcer, Diabetic ulcer)	Phase III	FunPep (Japan)	In-house/ FunPep
	Redasemide Trifluoroacetate	Mobilization of mesenchymal stem cells (MSCs) to peripheral blood (injection)	Stroke	Phase IIb	StemRIM (Japan)	In-house
			Epidermolysis bullosa	Phase II	StemRIM (Japan)	In-house
	S-531011	anti-CCR8 antibody (injection)	Solid tumor	Phase Ib/II	In-house	In-house
	S-740792	New mechanism of action (oral)	Walking impairment associated with multiple sclerosis	Phase I	In-house	In-house
	S-054501 (S-600918 + Concomitant drug X)	P2X3 receptor inhibitor (oral) + Mechanism of Concomitant drug	Sleep Apnea with a Central Component	Phase II	S-600918: In-house	In-house
	S-606001	Glycogen synthase 1 (GYS1) inhibitor (oral)	Pompe disease	Phase II	Maze (USA)	In-house
	SDS-881	AI Programmed Medical Device for Conversational Cognitive Function Testing	Cognitive impairment in dementia	Phase III	FRONTEO (Japan)	In-house
	S-898270	Phosphodiesterase 4D (PDE4D) Inhibitors	Alzheimer's Disease	Phase I	In-house	In-house
	S-054502 (Sulthiame)	Carbonic anhydrase inhibitor	Sleep Apnea	Phase II	Desitin (Germany)	In-house
	Cantharidin [YCANTH®topical solution0.71%]	Treatment for viral warts (Topical)	Common warts	Phase III	Verrica (USA)	In-house /Verrica
	TO-210	Peroxisome proliferator-activated receptor γ (PPAR γ) modulating agent (Topical)	Acne vulgaris	Phase III	Nogra (Ireland)	In-house
	TO-203 [MITICURE®House Dust Mite Sublingual Tablets]	Allergen Immunotherapy (Sublingual tablet)	House dust mite inducedallergic asthma	Phase II/III	ALK (Denmark)	In-house
	TO-209	Allergen Immunotherapy (Sublingual tablet)	Grass pollen-induced allergic rhinitis	Phase III	ALK (Denmark)	In-house
	Tapinarof	Aryl hydrocarbon receptor (AhR) modulating agent (Topical)	Atopic dermatitis in pediatric patients	NDA submission: Japan (Oct. 2025)	Dermavant (Switzerland)	In-house
			Atopic dermatitis in infant patients	Phase III	Dermavant (Switzerland)	In-house
	Delgocitinib	Janus kinase (JAK) inhibitor (Lotion Formulation)	Atopic dermatitis	NDA submission: Japan (Feb. 2026)	In-house	In-house
			Atopic dermatitis in pediatric patients	Phase III	In-house	In-house
	S-051051 (JTE-051)	Tropomyosin Receptor Kinase A (TrkA)/Interleukin-2 inducible T-cell kinase (ITK) inhibitor (oral)	Interstitial cystitis/Bladder pain syndrome, Autoinflammatory/Autoimmune diseases	Phase II	In-house	In-house
	S-662662 (JTT-662)	Sodium-Glucose Co-transporter1 (SGLT1) inhibitor (oral)	Hypertrophic cardiomyopathy	Phase I	In-house	In-house
	S-861861 (JTT-861)	Pyruvate dehydrogenase kinase (PDHK) inhibitor (oral)	Chronic heart failure	Phase II	In-house	In-house
	S-064064 (JTC-064)	PDHK inhibitor (oral)	Neurodegenerative disease	Phase I	In-house	In-house
	S-161161 (JTV-161)	Proto-oncogene serine/threonine-protein kinase1 (Pim-1) inhibitor (oral)	Pulmonary arterial hypertension	Phase I	In-house	In-house
	S-162162 (JTE-162)	NLR family pyrin domain containing 3 (NLRP3) inhibitor (oral)	Autoinflammatory/Autoimmune diseases	Phase I	In-house	In-house
	S-261261 (JTV-261)	Phospholipase D1/2 (PLD1/2) inhibitor (oral)	Thrombosis	Phase I	In-house	In-house
	S-262262 (JTC-262)	NLRP3 inhibitor (oral)	Neurodegenerative disease	Phase I	In-house	In-house
	S-263263 (JTV-263)	Hematopoietic Prostaglandin D Synthase (H-PGDS) inhibitor (oral)	Peripheral artery disease	Phase I	In-house	In-house
	S-461461 (JTE-461)	Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist (oral)	Chronic spontaneous urticaria	Phase I	In-house	In-house

<Out-Licensing Activity>

Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
S-723595 (TLC-3595)	Acetyl-CoA carboxylase 2 inhibitor (oral)	Type 2 diabetes	Phase IIa	In-house	OrsoBio, Inc. (USA)
S-365598	Integrase inhibitor (ultra long-acting injection)	HIV infection	Phase IIb (Oral)	In-house	SHIONOGI-ViiV Healthcare LLC
Delgocitinib	Janus kinase (JAK) inhibitor (Cream)	Chronic hand eczema	NDA submission: Mainland China (NMPA) (Sep. 2025)	In-house	LEO Pharma (Denmark)
		Chronic hand eczema in adolescents	MAV submission: EU (Nov. 2025) sNDA submission: US (Feb. 2026)	In-house	LEO Pharma (Denmark)
		Palmoplantar pustulosis	Phase IIa	In-house	LEO Pharma (Denmark)
		Lichen sclerosis	Phase III	In-house	LEO Pharma (Denmark)
	JAK inhibitor (eye drop)	Ophthalmology disease	Phase II	In-house	ROHTO (Japan)

Since May 12, 2026

Stage change	Cefiderocol (Pediatric) : Phase III→NDA submission: US (Apr. 2026) ,EU (May. 2026)
	Ensitrelvir Fumaric Acid (Treatment/Children, 6 to 11 years) : NDA submission: Japan→Approval (Jun,2026)
	Ensitrelvir Fumaric Acid (Post exposure prophylaxis of COVID-19) : NDA submission→Approval USA (Jun,2026)
	Secutrelvir: Phase II→Phase III
	Naldemedine tosilate (Peripheral opioid receptor antagonis) : NDA submission: Mainland China (NMPA) →Approval (May,2026)